EUCTR2015-000056-23-NL进行中（未招募）不适用
89Zr-rituximab PET/CT for detection of central nervous system lymphoma - ZoLa study
MC Utrecht0 个研究点开始时间: 2015年6月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patients who have signed informed consent
- •-Age = 18 years
- •-MR suspicion of a primary CNS lymphoma (homogeneous contrast enhancement, low MRI ADC values).
- •-Planned diagnostic biopsy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •-Pregnancy
- •-Contra-indications for brain biopsy e.g. coagulation disorder or poor clinical condition assessed as unfit for surgical procedure.
研究者
相似试验
已完成
不适用
89Zr-rituximab PET/CT for detection of central nervous system lymphomabrain tumour1002532310029211lymphomaNL-OMON42205niversitair Medisch Centrum Utrecht12
进行中（未招募）
不适用
The use of isotope-bound antibodies to visualize and subsequently treat B-cell lymphomaCD20 positive LymphomaMedDRA version: 14.0Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005474-38-BEInstitut Jules Bordet
招募中
2 期
89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.hereditary tumor syndrome1002239610029209NFNL-OMON52411eids Universitair Medisch Centrum24
进行中（未招募）
1 期
89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.eurofibromatosis type 2EUCTR2020-000156-35-NLeiden University Medical Center15
已完成
不适用
89Zr-bevacizumab labelled PET imaging in patients with Renal Cell Carcinoma treated with sunitinib or bevacizumab plus interferon; a pilot studyNL-OMON33835niversitair Medisch Centrum Groningen26